Clinical Trial Update: Effect of Alirocumab(Proprotein Convertase Subtilisin/Kexin type9 Inhibitor) and Rosuvastatin or Rosuvastatin Alone on Lipid Core Plaques in Coronary Artery Disease Evaluated by Near-infrared Spectroscopy Intravascular Ultrasound [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating the effect of alirocumab (PCSK9 inhibitor) with rosuvastatin versus rosuvastatin alone on lipid core plaques in coronary artery disea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angina Pectoris
• Coronary Artery Disease

Drugs mentioned

• Rosuvastatin (rosuvastatin)
• alirocumab (alirocumab)

Snippet

Sponsor: Kobe University | Conditions: Coronary Artery Disease, Angina Pectoris | Phase 4 | Status: UNKNOWN